Aptahem » News

Aptahem Newsletter March 2018

2018-03-21

CEO comments 2018 is very much underway, and we’re really building momentum – what a start to the year we’ve had! So much has happened in the barely three months since the beginning of the year, and I look...

Aptahem strengthens the company’s management team with the appointment of a new Chief Medical Officer in advance of the clinical program

2018-02-27

Aptahem AB (publ) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved in the disease process. Aptahem is today pleased to announce the appointment...

Aptahem’s scale-up process for an efficient larger-scale manufacture of Apta-1 is finalized

2018-02-20

Aptahem AB (Aktietorget: APTA) a biotechnology company which is developing aptamer-based drugs for the treatment of life-threatening conditions in which coagulation and inflammation work together in the disease process, announces that production process of the company´s drug candidate Apta-1...

Aptahem strengthens the company´s scientific advisory board with internationally recognised and highly qualified experts in advancement of clinical studies

2018-01-17

Aptahem is today pleased to announce the recruitment to the company´s scientific advisory board of Hans Peter Schwarz and Mats Eriksson; two highly experienced and internationally recognised experts. Professor Hans Peter Schwarz, MD has previously held leading positions within...

Aptahem has finalized an improved bioanalytical method for the measurement of Apta-1 in plasma

2017-12-20

Aptahem is now able to announce that the development of a completely new bioanalysis method has been finalized in collaboration with our partner Axolab in Germany. The new method has a better resolution and can detect lower levels of...

Interview with the Chairman of the Scientific Advisory Board, Dr Anders Bylock

2017-11-10

”Aptahem’s drug candidate shows sensationally good results in sepsis studies” The scientific advisory board has now been in place for almost a year, and we have interviewed the president of the board, Dr. Anders Bylock, about what has happened...

Aptahem submits patent application based on new results, drafts a prospectus supplement and extends subscription period

2017-10-03

Aptahem (publ) announced today that the company has submitted a new patent application based on the latest research results of Apta-1, with the aim of strengthening the company’s intellectual property rights portfolio. The new patent application is based on...

Apta-1 shows improved survival rate in extended study

2017-09-12

Aptahem (publ) can announce today new positive results from an extended study performed with Hooke Laboratories (US), the collaborating partner. The results show that intravenous administration of Apta-1 correlates with an improved survival rate in test animals. The outcome...

Aptahem presents a new development plan for Apta-1

2017-08-11

Aptahem AB (publ) can announce today that the company’s board has finalized a revised development plan for the drug candidate Apta-1. The new development plan was established together with the company’s scientific advisory board who assessed Apta-1’s pharmacological properties....

Aptahem enters into production agreement with BioSpring

2017-08-10

Aptahem AB (publ) can announce today that it has entered into a production agreement with BioSpring, a world-leading producer of oligonucleotides. BioSpring has been contracted to manufacture the substance in drug candidate Apta-1 for the company’s preclinical and upcoming...